ProMIS Neurosciences — Third Quarter 2026 Earnings Summary

ProMIS Neurosciences reported a net loss of $8.2 million for the third quarter of 2026, with cash reserves totaling $44.1 million as of September 30, 2026. The company's lead Alzheimer's candidate, PMN310, remains on track to deliver unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in the first quarter of 2027. Recent interim data showed no amyloid-related imaging abnormalities with edema and a 4.4% rate of hemorrhage, all of which were mild and asymptomatic. Ivana Rubino, Ph.D., a former senior executive at Biogen and Roche, was appointed Chief Commercial Officer effective October 5, 2026, to guide the company's late-stage development and commercial strategy.